BR9712424A - Composição farmacêutica antagonista deneurotrofina - Google Patents

Composição farmacêutica antagonista deneurotrofina

Info

Publication number
BR9712424A
BR9712424A BR9712424-9A BR9712424A BR9712424A BR 9712424 A BR9712424 A BR 9712424A BR 9712424 A BR9712424 A BR 9712424A BR 9712424 A BR9712424 A BR 9712424A
Authority
BR
Brazil
Prior art keywords
lower alkyl
pharmaceutical composition
alkyl
optionally substituted
neurotrophin
Prior art date
Application number
BR9712424-9A
Other languages
English (en)
Inventor
Ashok Tehim
Xiannong Chen
Original Assignee
Allelix Biopharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9621902.7A external-priority patent/GB9621902D0/en
Priority claimed from GBGB9710904.5A external-priority patent/GB9710904D0/en
Application filed by Allelix Biopharma filed Critical Allelix Biopharma
Publication of BR9712424A publication Critical patent/BR9712424A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO FARMACêUTICA ANTAGONISTA DENEUROTROFINA". Uma composição farmacêuticacompreendendo um composto de formula (I) onde R1 éselecionado dentre , inter alia, alquila, aril-alquila inferior, alquilainferior-heterocíclico, carbonato-alquila inferior; aminoopcionalmente substituído; benzidimaz 2-il; fenila opcionalmentesubstituído; alquila inferior (R5), (R6) onde um de R5 ou R6 éselecionado dentre H e alquila inferior e o outro é selecionadodentre carboxila, carboxi-alquila inferior e alcóxi carbonila inferior;NHCH2CH20X onde X representa um éster hidrolizável in vivo; eR2 e R3 são independentemente selecionados dentre H, NO2,Halo, di(alquila inferior)amino, ciano, C(O)OH, fenil-S-, alquilainferior, e Z(O)OR7 onde Z é selecionado dentre C e S e R7 éselecionado dentre H, alquila amino inferior e arilamino; ou saisfarmaceuticamente aceitáveis ou certos ésteres hidrolizáveis invivo ou amidos do mesmo, em uma quantidade efetiva para inibiratividade mediada por neurotrofina e um portador apropriado, édescrita. As composições são úteis para inibir atividade mediadapor neurotrofina tal como o crescimento de neurito que ocorre emalguns estados de doenças neurodegenarativas.
BR9712424-9A 1996-10-21 1997-10-20 Composição farmacêutica antagonista deneurotrofina BR9712424A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9621902.7A GB9621902D0 (en) 1996-10-21 1996-10-21 Neurotrophin antagonist compositions
GBGB9710904.5A GB9710904D0 (en) 1997-05-27 1997-05-27 Neurotropin antagonist compositions
PCT/CA1997/000779 WO1998017278A1 (en) 1996-10-21 1997-10-20 Neurotrophin antagonist compositions

Publications (1)

Publication Number Publication Date
BR9712424A true BR9712424A (pt) 2001-11-20

Family

ID=26310264

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712424-9A BR9712424A (pt) 1996-10-21 1997-10-20 Composição farmacêutica antagonista deneurotrofina

Country Status (14)

Country Link
US (4) US20020169182A1 (pt)
EP (1) EP0930883B1 (pt)
JP (1) JP2001503397A (pt)
KR (1) KR20000052691A (pt)
AT (1) ATE315397T1 (pt)
AU (1) AU728523C (pt)
BR (1) BR9712424A (pt)
CA (1) CA2268450C (pt)
DE (1) DE69735090T2 (pt)
DK (1) DK0930883T3 (pt)
ES (1) ES2257768T3 (pt)
IL (1) IL129475A0 (pt)
NZ (1) NZ335291A (pt)
WO (1) WO1998017278A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2268450C (en) 1996-10-21 2008-08-05 Allelix Biopharmaceuticals, Inc. Neurotrophin antagonist compositions
CZ20011782A3 (cs) * 1998-11-25 2001-09-12 Merck Patent Gmbh Derivát benzo[de]isochinolin-1,3-dionu, způsob jeho přípravy, jeho použití a farmaceutický prostředek, který ho obsahuje
AU1504900A (en) * 1998-11-25 2000-06-13 Merck Patent Gmbh Substituted benzo(de)isoquinoline-1,3-diones
US6492380B1 (en) 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding
US6468990B1 (en) 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
FR2807660A1 (fr) * 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
AU2003285864C1 (en) 2002-10-08 2010-07-01 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering a nerve growth factor antagonist and compositions containing the same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
NZ587852A (en) 2002-12-24 2012-02-24 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
PL1732949T3 (pl) 2004-04-07 2010-06-30 Rinat Neuroscience Corp Sposoby leczenia nowotworowego bólu kości przez podawanie antagonisty czynnika wzrostu nerwów
GB0419850D0 (en) * 2004-09-07 2004-10-13 Angeletti P Ist Richerche Bio Therapeutic agents
AU2006291927A1 (en) * 2005-09-15 2007-03-22 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
US20090082368A1 (en) * 2007-09-24 2009-03-26 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
FR2953839A1 (fr) * 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
LT3333188T (lt) 2010-08-19 2022-06-10 Zoetis Belgium S.A. Anti-ngf antikūnai ir jų panaudojimas
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
CN104364264B (zh) 2012-06-06 2018-07-24 硕腾服务有限责任公司 犬源化抗ngf抗体和其方法
US10982002B2 (en) 2018-03-12 2021-04-20 Zoetis Services Llc Anti-NGF antibodies and methods thereof
US20230348608A1 (en) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Treatment Of Arthropathy Based Upon Stratification Of Osteoarthritis Polygenic Risk Score

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US525841A (en) * 1894-09-11 Baling-press
US627129A (en) * 1899-06-20 Collar-edge-ironing machine
US3821383A (en) * 1972-07-10 1974-06-28 Ayerst Mckenna & Harrison Compositions for and a method of treating diabetic complications
US4006238A (en) * 1975-08-28 1977-02-01 E. R. Squibb & Sons, Inc. Use of 2-(hydroxyalkyl)-1H-benz[de]isoquinoline-1,3(2H)-diones as anti-allergy agents
ES459497A1 (es) * 1977-06-04 1978-04-16 Made Labor Sa Un metodo para la preparacion industrial de naftalimidas y sus derivados.
US4254109A (en) * 1979-11-08 1981-03-03 Ayerst, Mckenna & Harrison Inc. 1H-Benz[de]isoquinoline-2(3H)-acetic acid derivatives
RU2051677C1 (ru) * 1982-02-10 1996-01-10 Украинский научно-исследовательский институт эндокринологии и обмена веществ Средство для профилактики и лечения диабетических осложнений, ангиопатий, нейропатий, катаракты
US5183821A (en) * 1983-09-19 1993-02-02 Laboratories Knoll, S.A. Method for treating leukemias using N-(2-dimethylaminoethyl)-3-amino-1,8-naphthalimide for treating leukemias and solid tumors
IT1214618B (it) * 1985-06-27 1990-01-18 I P A International Pharmaceut Composti e composizioni farmaceutiche per la terapia di retinopatie e neuropatie diabetiche.
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
DE3707651A1 (de) * 1987-03-10 1988-09-22 Knoll Ag Bis-naphthalimide, ihre herstellung und verwendung
DE3707652A1 (de) * 1987-03-10 1988-09-22 Knoll Ag Verwendung von benzo(de)isochinolin-1,3-dionen zur herstellung von arzneimitteln
US5420137A (en) * 1989-07-11 1995-05-30 Knoll Ag Amonafide salts
US5356906A (en) * 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
CA2030129A1 (en) * 1989-11-29 1991-05-30 Thomas Saupe 1,8-napthalenedicarboximides as antidotes
US5342942A (en) * 1992-06-09 1994-08-30 Warner-Lambert Company Pyrazoloquinazolone derivatives as neurotrophic agents
DE4232739A1 (de) * 1992-09-30 1994-03-31 Knoll Ag Neue asymmetrisch substituierte bis-Naphthalimide
IL110460A (en) * 1993-08-18 2001-01-11 Basf Ag Bite-naphthalimides, their preparation and pharmaceutical preparations containing them
US6291247B1 (en) * 1994-05-11 2001-09-18 Queen's University At Kingston Methods of screening for factors that disrupt neurotrophin conformation and reduce neurotrophin biological activity
GB9616105D0 (en) * 1996-07-31 1996-09-11 Univ Kingston TrkA binding site of NGF
CA2268450C (en) 1996-10-21 2008-08-05 Allelix Biopharmaceuticals, Inc. Neurotrophin antagonist compositions
DK1093819T3 (da) 1997-02-07 2006-09-11 Emisphere Tech Inc Forbindelse og præparat til tilförsel af aktive midler
AU7449198A (en) 1997-05-21 1998-12-11 Japan Tobacco Inc. Phthalimide derivatives and pharmaceutical containing said derivatives
WO2000000472A1 (en) 1998-06-30 2000-01-06 Du Pont Pharmaceuticals Company 5-ht7 receptor antagonists
KR100364205B1 (ko) * 1998-07-03 2002-12-11 다이호야쿠힌고교 가부시키가이샤 나프탈이미도벤즈아미드 유도체 또는 그의 염
US6468990B1 (en) * 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
US6492380B1 (en) * 1999-05-17 2002-12-10 Queen's University At Kingston Method of inhibiting neurotrophin-receptor binding

Also Published As

Publication number Publication date
EP0930883B1 (en) 2006-01-11
ATE315397T1 (de) 2006-02-15
CA2268450A1 (en) 1998-04-30
DE69735090T2 (de) 2006-09-14
ES2257768T3 (es) 2006-08-01
IL129475A0 (en) 2000-02-29
DE69735090D1 (de) 2006-04-06
AU4696897A (en) 1998-05-15
US7291629B2 (en) 2007-11-06
KR20000052691A (ko) 2000-08-25
US20090215815A1 (en) 2009-08-27
US20020169182A1 (en) 2002-11-14
WO1998017278A1 (en) 1998-04-30
US20080287484A1 (en) 2008-11-20
CA2268450C (en) 2008-08-05
NZ335291A (en) 2001-02-23
JP2001503397A (ja) 2001-03-13
AU728523C (en) 2001-08-09
EP0930883A1 (en) 1999-07-28
AU728523B2 (en) 2001-01-11
US20050250807A1 (en) 2005-11-10
DK0930883T3 (da) 2006-05-22

Similar Documents

Publication Publication Date Title
BR9712424A (pt) Composição farmacêutica antagonista deneurotrofina
IT1314184B1 (it) Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
NZ501346A (en) Valinyl aromatic beta amino acid dipeptide compounds having fungicidal activity and their agronomic use
ATE277066T1 (de) Bicyclonucleosid-analoga
IL144826A0 (en) Amide compounds and pharmaceutical compositions containing the same
NO20003018L (no) Triazinangiogenese-inhibitorer
FI954609A (fi) 1-amidinofenyyli-pyrrolidoneja, -piperidinoneja ja -atsetinoneja verihiutaleiden kasaantumisen inhibiittoreina
MY109846A (en) Dual inhibitors of no synthase and cyclooxygenase, process for their preparation and therapeutical compositions containing them
BG106020A (en) Inhibitors of impdh enzyme
ATE287715T1 (de) Verwendung von oxidosqualencyclasehemmer zur senkung des cholesterinblutspiegels
DE60019317D1 (de) Chinazolinderivate
TW430660B (en) Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them
NO991494L (no) <beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer
HUP0100732A2 (hu) Amidvegyületet és azolszármazékot tartalmazó szinergetikus hatású fungicid kompozíció és alkalmazása
CA2250861A1 (en) Cyclic adhesion inhibitors
RS50046B (sr) Farmaceutske kompozicije tizoksanida i nitazoksanida
PL341050A1 (en) Heterocyclic cytoxic agents
ES2093091T3 (es) Derivado de glutation.
KR950002753A (ko) 연골 보호제
BR0315400A (pt) Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer em um paciente e para inibir o crescimento de uma célula de câncer ou célula neoplástica
HUP0101996A2 (hu) Szinergetikus fungicid hatóanyag keverék és alkalmazása
BR0307266A (pt) Compostos que inibem a atividade do fator xa
BR0209776A (pt) Composições de inibidores seletivos de ciclo oxigenase-2 e radiação para inibição ou prevenção de doença cardiovascular
HUP0202340A2 (hu) Hatóanyagként kondenzált heterociklusos vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO20014268D0 (no) Syrekatalyserte reaksjoner

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]